Comparing Oncocyte (IMDX) & Its Competitors

Oncocyte (NASDAQ:IMDX) is one of 859 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Oncocyte to similar businesses based on the strength of its analyst recommendations, valuation, dividends, institutional ownership, risk, earnings and profitability.

Volatility and Risk

Oncocyte has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, Oncocyte’s rivals have a beta of 1.25, meaning that their average stock price is 25% more volatile than the S&P 500.

Earnings & Valuation

This table compares Oncocyte and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oncocyte	$4.05 million	-$50.22 million	-2.69
Oncocyte Competitors	$686.75 million	$8.86 million	-11.60

Oncocyte’s rivals have higher revenue and earnings than Oncocyte. Oncocyte is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Oncocyte and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
Oncocyte Competitors	-9,423.54%	-126.74%	-33.07%

Insider & Institutional Ownership

55.3% of Oncocyte shares are owned by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology” companies are owned by institutional investors. 2.2% of Oncocyte shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Oncocyte and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1	0	2	0	2.33
Oncocyte Competitors	9417	14910	44589	1507	2.54

Oncocyte currently has a consensus price target of $10.50, suggesting a potential upside of 162.17%. As a group, “Biotechnology” companies have a potential upside of 60.37%. Given Oncocyte’s higher possible upside, analysts plainly believe Oncocyte is more favorable than its rivals.

Summary

Oncocyte beats its rivals on 7 of the 13 factors compared.

About Oncocyte

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.